The goal of this project is to conduct clinical trials that will show that photodynamic therapy (PDT) has a pivotal role in improving tumor response and quality of life (QoL) for patients with head and neck squamous cell carcinoma (HNSCC). To that end we will designed three trials. The first trial is a randomized three-center Phase II study for patients with T1/T2 N0 squamous cell carcinoma (SCC) of the oral cavity. Surgery, the preferred therapy, is often associated with loss of organ function. HPPH mediated PDT has shown promising results in treating these tumors without loss of organ function. We hypothesize that PDT with HPPH is an organ sparing therapy that has the potential to effectively treat patients with T1/T2 N0 SCC of the oral cavity, in comparison to standard surgery. The second trial is a randomized three-center Phase II study for patients with locally advanced recurrent HNSCC that have failed radiation therapy. The SoC chemotherapy (platinum base, 5-fluorouracil plus Cetuximab) yields objective response rates of 36%, at best. A nonrandomized Phase II trial with interstitial PDT (I-PDT) has shown promise by achieving overall response rate of 74% in the treatment of locally advanced recurrent HNSCC. We hypothesize that I-PDT with SoC chemotherapy will improve tumor response in patients with locally advanced recurrent HNSCC that failed radiation therapy, in comparison to SoC chemotherapy alone. The third trial is a Phase I vaccine study testing the safety of a PDT- generated vaccine for patients with HNSCC and positive lymph nodes, which is the strongest prognosis for poor clinical outcomes. We hypothesize that surgical resection of HNSCC followed by vaccination with PDT generated vaccine can be performed safely and will enhance anti-tumor T cell activation and responses against HNSCC tumors. Our hypotheses will be tested in the following Specific Aims: 1. To perform a randomized multi-center Phase II trial with HPPH-PDT for the treatment of T1/T2 N0 SCC of the oral cavity. 2. To perform a randomized multi-center Phase II trial with HPPH mediated I-PDT and SoC chemotherapy for the treatment of patients with locally advanced recurrent HNSCC that failed radiation therapy. 3. To perform a Phase I combination trial of surgery followed by HPPH PDT generated vaccine for the treatment of patients with HNSCC and positive lymph nodes.

Public Health Relevance

Standard treatment for cancer of the head and neck involves the use of surgery, chemotherapy and radiation therapy. These therapies impair the quality of life of patients with early disease, and are of limited efficacy for patients with advanced disease. The goal of this project is to show that photodynamic therapy can be used to improve clinical outcomes, with fewer side effects, in patients with early and advanced head and neck cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA055791-23
Application #
9207446
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
23
Fiscal Year
2017
Total Cost
$181,319
Indirect Cost
$62,180
Name
Roswell Park Cancer Institute Corp
Department
Type
Independent Hospitals
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Shafirstein, Gal; Bellnier, David A; Oakley, Emily et al. (2018) Irradiance controls photodynamic efficacy and tissue heating in experimental tumours: implication for interstitial PDT of locally advanced cancer. Br J Cancer 119:1191-1199
Tracy, Erin C; Bowman, Mary-Jo; Pandey, Ravendra K et al. (2018) Cell-specific Retention and Action of Pheophorbide-based Photosensitizers in Human Lung Cancer Cells. Photochem Photobiol :
Egan, Shawn M; Karasik, Ellen; Ellis, Leigh et al. (2017) miR-30e* is overexpressed in prostate cancer and promotes NF-?B-mediated proliferation and tumor growth. Oncotarget 8:67626-67638
Harris, Kassem; Oakley, Emily; Bellnier, David et al. (2017) Endobronchial ultrasound-guidance for interstitial photodynamic therapy of locally advanced lung cancer-a new interventional concept. J Thorac Dis 9:2613-2618
Hall, Brandon M; Balan, Vitaly; Gleiberman, Anatoli S et al. (2017) p16(Ink4a) and senescence-associated ?-galactosidase can be induced in macrophages as part of a reversible response to physiological stimuli. Aging (Albany NY) 9:1867-1884
Shafirstein, Gal; Bellnier, David; Oakley, Emily et al. (2017) Interstitial Photodynamic Therapy-A Focused Review. Cancers (Basel) 9:
Saenz, Courtney; Cheruku, Ravindra R; Ohulchanskyy, Tymish Y et al. (2017) Structural and Epimeric Isomers of HPPH [3-Devinyl 3-{1-(1-hexyloxy) ethyl}pyropheophorbide-a]: Effects on Uptake and Photodynamic Therapy of Cancer. ACS Chem Biol 12:933-946
Oakley, Emily; Bellnier, David A; Hutson, Alan et al. (2017) Surface markers for guiding cylindrical diffuser fiber insertion in interstitial photodynamic therapy of head and neck cancer. Lasers Surg Med 49:599-608
Brackett, Craig M; Kojouharov, Bojidar; Veith, Jean et al. (2016) Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. Proc Natl Acad Sci U S A 113:E874-83
Mimikos, Christina; Shafirstein, Gal; Arshad, Hassan (2016) Current state and future of photodynamic therapy for the treatment of head and neck squamous cell carcinoma. World J Otorhinolaryngol Head Neck Surg 2:126-129

Showing the most recent 10 out of 167 publications